Tianshu Pharmaceutical Debuts at CPHI China 2026 in Shanghai: One-Stop CDMO Solutions Empower Global Partners

　　The 24th CPHI China 2026 was held at Shanghai New International Expo Centre from June 16 to 18. Hubei Tianshu Pharmaceutical Co., Ltd. (Tianshu Pharmaceutical), alongside its parent company Nanjing Vcare PharmaTech Co.,Ltd. (Nanjing Vcare), showcased its full portfolio including innovative drug CDMO services, high-end APIs and advanced pharmaceutical intermediates, presenting integrated full-industry-chain solutions to pharmaceutical enterprises at home and abroad.

　　Committed to evolving into a world-class supplier and comprehensive solution provider of innovative drug CDMO services, high-end APIs and advanced pharmaceutical intermediates, Tianshu Pharmaceutical concentrates on custom manufacturing of pharmaceutical intermediates and APIs while advancing its green manufacturing platforms. The company consistently builds core technological strengths centered on synthetic biology and continuous production technologies. In addition, it has established a sound quality management system and high-standard production facilities capable of large-scale manufacturing of complex processes. All workshops are constructed in full alignment with global compliance standards including FDA, EU GMP and ICH guidelines, enabling the delivery of customized one-stop services ranging from process scale-up to commercial production.

　　At Booth W3E36, Tianshu Pharmaceutical’s team engaged in face-to-face communications with representatives of pharmaceutical firms worldwide. Through product catalog displays and technical case sharing, the team highlighted core competitive edges such as high-barrier advanced pharmaceutical intermediates and custom manufacturing of specialty APIs, drawing crowds of domestic and international pharmaceutical companies for on-site business discussions. CPHI Shanghai serves as a vital platform for Tianshu Pharmaceutical to deepen global cooperation and expand overseas markets, further consolidating its service strengths within the global pharmaceutical industrial chain.

　　Taking CPHI China 2026 as a hub for global collaboration, Tianshu Pharmaceutical will further strengthen industrial links with partners domestically and internationally. The company will ramp up R&D investment in green manufacturing technologies and expand compliant intelligent production capacity. With differentiated proprietary technologies, end-to-end one-stop services and reliable global delivery capabilities, Tianshu Pharmaceutical​​​​​​​ will fully empower the industrialization of innovative drugs worldwide and drive China’s pharmaceutical manufacturing sector toward the high end of the global value chain.